Acumen Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ABOS Nasdaq 8731 https://acumenpharm.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call Transcript - Nov 14th, 2023 1:53 pm
Q3 2023 Acumen Pharmaceuticals Inc Earnings Call - Nov 14th, 2023 4:08 am
Acumen Pharmaceuticals Inc (ABOS) Reports Q3 2023 Financial Results and Provides Business Update - Nov 13th, 2023 3:54 pm
Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals? - Nov 13th, 2023 2:31 pm
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights - Nov 13th, 2023 12:00 pm
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures - Nov 13th, 2023 12:00 pm
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference - Nov 7th, 2023 9:01 pm
Q3 2023 Halozyme Therapeutics Inc Earnings Call - Nov 7th, 2023 4:22 pm
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023 - Nov 6th, 2023 9:01 pm
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology - Nov 6th, 2023 12:30 pm
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference - Nov 2nd, 2023 8:00 pm
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease - Oct 27th, 2023 1:25 pm
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) - Oct 4th, 2023 12:00 pm
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference - Sep 19th, 2023 8:00 pm
Acumen Pharmaceuticals, Inc.'s (NASDAQ:ABOS) largest shareholders are private equity firms with 38% ownership, individual investors own 26% - Sep 17th, 2023 12:19 pm
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference - Sep 6th, 2023 8:00 pm
Q2 2023 Acumen Pharmaceuticals Inc Earnings Call - Aug 9th, 2023 2:21 am
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights - Aug 8th, 2023 11:00 am
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023 - Aug 1st, 2023 8:00 pm
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans - Jul 25th, 2023 5:47 pm